Inside 340B Report podcast

Episode 45: New HRSA Rebate Model, SUSTAIN 340B Act Introduced, Analysis of Decreasing WAC Prices

0:00
28:36
Rewind 15 seconds
Fast Forward 15 seconds

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: the Health Resources and Services Administration's (HRSA) newly unveiled 340B rebate pilot; the introduction of the long-anticipated bipartisan Senate SUSTAIN 340B Act; and a new 340B Report analysis on how lower list prices are impacting 340B savings. 

 

Key Topics Covered:

 

Rebate Model 2.0

Will breaks down the details of HRSA's revised 340B rebate pilot, which is scheduled to take effect Jan. 1, 2027, and apply to drugs subject to Medicare price negotiations for the 2026 and 2027 cycles. Shannon notes that provider groups panned the policy, arguing it would undermine their ability to serve vulnerable patients, while the drug industry praised it and say it is a step toward program transparency. Will explains that the new pilot appears on stronger legal footing than the agency's first attempt that was blocked in federal court. However, he notes, another lawsuit is still likely. 

 

Meanwhile, On Capitol Hill

Shannon discusses the long awaited Senate "Group of 6's" newly introduced SUSTAIN 340B Act. She notes that the 97-page bill would codify the use of contract pharmacies, end the 340B rebate model within one year and establish a neutral data clearinghouse, among other reforms..  Luke dives into his reporting on how stakeholders reacted to the bill and Ted provides information on what he is hearing from one of the key stakeholder groups. 

 

Reduced WAC Prices Impacting Covered Entities

Luke discusses his reporting on how lower wholesale acquisition costs (WAC) are impacting 340B revenue for covered entities. He explores how new policies, like the Medicare drug price negotiations and new Medicare inflationary penalties, are leading some drugmakers to lower their list prices, and in turn reducing providers' 340B savings. Luke notes that some covered entities have already seen a decrease of $1 million so far in 2026, which translated into less wraparound services for patients. 

 

Subscribe & Stay Updated

 

How to Follow Us and Learn More About This Episode's Sponsor

 

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

 

This episode is brought to you by one of our great Ultra Diamond sponsors, CompassRx. CompassRx is the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. We are very grateful to CompassRx for its sponsorship. 

 

Subscribe to 340B Report with a Special Discount

 

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

More episodes from "Inside 340B Report"